GlaxoSmithKline Pharmaceuticals Limited has successfully completed its postal ballot process, with shareholders decisively approving the appointment of Mr. Ronojit Biswas in dual leadership roles. The company announced the results on April 8, 2026, following the conclusion of the electronic voting period.

Postal Ballot Results Overview

The pharmaceutical company conducted the postal ballot process through remote e-voting for two ordinary resolutions related to Mr. Ronojit Biswas's appointments. The voting period commenced on March 9, 2026, at 09:00 a.m. and concluded on April 8, 2026, at 05:00 p.m.

Resolution 1: Director Appointment

The first resolution for appointing Mr. Ronojit Biswas (DIN: 07684843) as Director received overwhelming support from shareholders across all categories.

Resolution 2: CFO Appointment

The second resolution for appointing Mr. Ronojit Biswas as Whole-time Director & Chief Financial Officer demonstrated even stronger support from shareholders.

Scrutinizer Report Highlights

P.N. Parikh of Parikh & Associates, serving as the appointed scrutinizer, confirmed the validity of the voting process. The scrutinizer's report detailed the comprehensive e-voting procedure conducted through KFintech's platform.

Corporate Governance Compliance

The postal ballot process was conducted in full compliance with Section 110 of the Companies Act, 2013, and the Companies (Management and Administration) Rules, 2014. The company also adhered to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The voting results and scrutinizer's report have been made available on the company's website and KFintech's e-voting platform, ensuring transparency in the corporate governance process. With these appointments approved, Mr. Ronojit Biswas will assume his roles as Director and Chief Financial Officer, contributing to the company's leadership structure.

GlaxoSmithKline Pharmaceuticals Limited has informed stock exchanges about receiving a final order from the TDS Authority imposing a demand liability of Rs 2.01 crores. The pharmaceutical company disclosed this development under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

TDS Demand Details

The demand order pertains to the assessment year 2020-21 and was issued by the TDS Authority – INT Tax Circle 2(3)(2). The total liability breaks down into two components: Rs 1.11 crores in TDS demand and Rs 0.90 crores in interest charges.

Nature of Assessment

The demand liability has been issued under TDS default provisions under Section 201 of the Income Tax Act. The assessment order was issued under Section 201(1)/201(1A) and was received by the company on 31st March, 2026.

Company's Response and Financial Impact

GlaxoSmithKline Pharmaceuticals has indicated it will contest the assessment order through appropriate legal channels. The company stated it is in the process of filing an appeal before the appellate authority to challenge the demand.

Regarding financial implications, the company has clarified that there will be no impact on its financial statements at this stage. This position is based on the company's decision to contest the assessment order through the appeals process.

Regulatory Compliance

The disclosure was made in compliance with stock exchange regulations, with the company informing both BSE Limited and the National Stock Exchange of India Limited about the development. The communication was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, ensuring proper corporate governance protocols were followed.